Iwadate Y, Namba H, Yamaura A
Department of Neurosurgery, Chiba University, School of Medicine, Japan.
Anticancer Res. 2000 Jan-Feb;20(1B):573-7.
We investigated the role of surgery in the treatment of multiple brain metastases when performed with radiation therapy.
One hundred and thirty-eight patients who underwent resection for brain metastases and received 30 Gy or more of adjuvant radiation therapy were entered into this study. Seventy-seven of the 138 patients (56%) had single brain metastases (Single Group), while the remaining 61 patients (44%) had multiple foci (Multiple Group). The 138 patients were divided into four subgroups; patients in Single Group treated with total or subtotal resection (Group A), those in Multiple Group who underwent total or subtotal resection and had remaining tumors smaller than 2 cm (Group B), those in Single Group treated with partial resection (Group C), and the other patients in Multiple Group (Group D).
The median survival was 8.7 and 9.2 months for the Single Group and the Multiple Group, respectively (not statistically different). The median survival was 9.6, 12.4, 3.7, and 4.5 months for Groups A, B, C, and D, respectively. Survival duration differed significantly between Groups A/B and Groups C/D (p < 0.05).
Surgical reduction of tumor volume which is approximately larger than 2 cm improves the efficacy of adjuvant radiation therapy and contributes to survival even in the patients with multiple brain metastases.
我们研究了手术联合放射治疗在多脑转移瘤治疗中的作用。
138例接受脑转移瘤切除术并接受30 Gy或更多辅助放射治疗的患者纳入本研究。138例患者中,77例(56%)有单个脑转移瘤(单发病灶组),其余61例(44%)有多个病灶(多发病灶组)。138例患者分为四个亚组:单发病灶组中接受全切除或次全切除的患者(A组),多发病灶组中接受全切除或次全切除且残留肿瘤小于2 cm的患者(B组),单发病灶组中接受部分切除的患者(C组),以及多发病灶组中的其他患者(D组)。
单发病灶组和多发病灶组的中位生存期分别为8.7个月和9.2个月(无统计学差异)。A、B、C、D组的中位生存期分别为9.6、12.4、3.7和4.5个月。A/B组和C/D组的生存时间差异有统计学意义(p<0.05)。
手术缩小体积约大于2 cm的肿瘤可提高辅助放射治疗的疗效,即使对于多脑转移瘤患者也有助于延长生存期。